Background:To compare the efficacy and safety of monthly administrations of gonadotropin releasing hormone (GnRH) agonists LY01005 and Zoladex ? in Chinese patients with premenopausal breast cancer. Methods:From October 2020 to November 2021, 188 premenopausal breast cancer patients were enrolled in 34 hospitals and randomized 1:1 to receive either LY01005 or Zoladex ? every 28 days for a total of three injections. All patients concomitantly received oral tamoxifen (TAM). The primary efficacy endpoint was cumulative probability of maintaining menopausal level [oestradiol (E2) ≤30 pg/ml] from day 29 to day 85. The second efficacy endpoint included changes in E2, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) compared with the baseline. Pharmacokinetics (PK), pharmacodynamics (PD), and safety were analyzed. The study also evaluated the pharmacokinetic and pharmacodynamic characteristics of LY01005. Results:A total of 188 patients were randomised and 187 patients received either LY01005 or Zoladex ?. Cumulative probabilities of maintaining menopausal level (E2≤30 pg/ml) from day 29 to day 85 were 93.1% for LY01005 and 86.3% for Zoladex ?. The between-group difference was 6.8% (95% CI: -2.3%, 15.9%) and primary efficacy in the LY01005 group was not inferior to that in the Zoladex ? group. Changes in E2, LH, and FSH levels compared with the baseline were equivalent between the two groups (E2: 89.34% to 90.23% vs. 82.11% to 85.02%; LH: 88.89% to 95.52% vs. 89.70% to 97.02%; FSH: 75.36% to 80.85% vs.73.07% to 80.24%, respectively). After three consecutive doses of LY01005, the LH and FSH levels of the subjects showed a transient increase after the first dose, reached a peak on the second day and then started to decrease. The LH and FSH reached a lower level and remained at or below that level until the 85th day. Both treatments were well-tolerated. Conclusion:LY01005 is as effective as Zoladex ? in suppressing E2 to menopausal levels in Chinese patients with premenopausal breast cancer, with a similar safety profile.

Background:To compare the efficacy and safety of monthly administrations of gonadotropin releasing hormone (GnRH) agonists LY01005 and Zoladex ? in Chinese patients with premenopausal breast cancer. Methods:From October 2020 to November 2021, 188 premenopausal breast cancer patients were enrolled in 34 hospitals and randomized 1:1 to receive either LY01005 or Zoladex ? every 28 days for a total of three injections. All patients concomitantly received oral tamoxifen (TAM). The primary efficacy endpoint was cumulative probability of maintaining menopausal level [oestradiol (E2) ≤30 pg/ml] from day 29 to day 85. The second efficacy endpoint included changes in E2, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) compared with the baseline. Pharmacokinetics (PK), pharmacodynamics (PD), and safety were analyzed. The study also evaluated the pharmacokinetic and pharmacodynamic characteristics of LY01005. Results:A total of 188 patients were randomised and 187 patients received either LY01005 or Zoladex ?. Cumulative probabilities of maintaining menopausal level (E2≤30 pg/ml) from day 29 to day 85 were 93.1% for LY01005 and 86.3% for Zoladex ?. The between-group difference was 6.8% (95% CI: -2.3%, 15.9%) and primary efficacy in the LY01005 group was not inferior to that in the Zoladex ? group. Changes in E2, LH, and FSH levels compared with the baseline were equivalent between the two groups (E2: 89.34% to 90.23% vs. 82.11% to 85.02%; LH: 88.89% to 95.52% vs. 89.70% to 97.02%; FSH: 75.36% to 80.85% vs.73.07% to 80.24%, respectively). After three consecutive doses of LY01005, the LH and FSH levels of the subjects showed a transient increase after the first dose, reached a peak on the second day and then started to decrease. The LH and FSH reached a lower level and remained at or below that level until the 85th day. Both treatments were well-tolerated. Conclusion:LY01005 is as effective as Zoladex ? in suppressing E2 to menopausal levels in Chinese patients with premenopausal breast cancer, with a similar safety profile.

Objective:To investigate the effects of endocrine drugs on tumor markers and endometrium after breast cancer surgery.Methods:Eighty-eight patients with endocrine therapy for breast cancer admitted to the Heping Hospital Affiliated to Changzhi Medical College from November 2018 to March 2022 were selected, 44 patients taken orally tamoxifen citrate tablets were enrolled in the study group, 44 patients taken orally anastrozole tablets were enrolled in the control group, the patients in the two groups were treated for 12 months. The tumor markers, endometrial thickness were compared between the two groups before treatment and 12 months after treatment. The drug safety was compared too.Results:After treatment, the serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125) and glycochain antigen 15-3 (CA15-3) in both groups were decreased, and the level of tumor markers in the study group were lower than those in the control group: (3.01 ± 0.23) μg/L vs.(3.89 ± 1.15) μg/L, (4.22 ± 1.21) kU/L vs. (7.38 ± 2.19) kU/L, (16.76 ± 2.19) kU/L vs. (19.87 ± 2.21) kU/L, there were statistical differences ( P<0.05). The endometrial thickness in the study group at 6 months and 12 months after treatment were higher than those in the control group: (7.23 ± 0.22) mm vs. (6.21 ± 0.19)mm, (7.98 ± 0.24) mm vs. (6.47 ± 0.22) mm, there were statistical differences ( P<0.05). At 12 months after treatment, the scores of functional dimension, emotional dimension, social/family dimension and physical dimension in functional assessment of cancer therapy (FACT-G) scale in the study group were significantly higher than those in the control group ( P<0.05). There was no statistically significant difference in adverse reactions between the two groups ( P>0.05). Conclusions:Tamoxifen citrate tablets can effectively inhibit the levels of serum tumor markers and improve the quality of life of patients, and anastrozole tablets can significantly reduce the endometrial thickness of breast cancer patients.

Objective:To study the expression of Proline rich protein11 (PRR11) in breast cancer and its relationship with clinical biological behavior, prognosis and survival.Methods:A prospective analysis method was used to select 80 patients with breast cancer from Jan. 2018 to Jan. 2019. Immunohistochemical S-P method was used to detect the expression of PRR11 in cancer tissues. Patients with positive expression of PRR11 were set as the study group ( n=47) and the patients with negative expression of PRR11 were set as the control group ( n=33) . All patients were followed up for 3 years to analyze and compare the survival rates of patients with positive and negative expression of PRR11. The relationship between PRR11 expression and clinical biological behavior, prognosis and survival was analyzed by Cox risk ratio review model. Results:80 patients were followed up for 3 years. It was found that the prognosis of patients with negative PRR11 expression was significantly better than that of patients with positive PRR11 expression ( χ2=5.75, P<0.001) . Chi square test was used to analyze the correlation between the expression of PRR11 and tumor size, TNM stage, lymph node metastasis, distant metastasis, histological grade, Ki67 expression and hormone receptor status ( P<0.05) . The expression of PRR11 in breast cancer tissues with larger tumors, distant metastasis and later staging was relatively high ( P<0.05) . Univariate Cox regression analysis showed that histological grade, TNM stage and PRR11 were independent risk factors affecting the prognosis of breast cancer patients ( P<0.001) . The AUC of prognosis prediction in patients with breast cancer was 0.812, and the 95% CI was 0.635-0.796. When PRR11 expression was positive, the sensitivity was 81.47%, and the specificity was 85.57%. Conclusions:The expression of PRR11 is relatively high in the late stage breast cancer tissue. The expression of PRR11 is closely related to the clinical biological behavior of breast cancer size, TNM stage and lymph node metastasis. The survival rate of patients with high PRR11 expression is low, and the positive expression of PRR11 is an independent risk factor affecting the prognosis of breast cancer patients. PRR11 detection has preferable clinical application value in predicting the prognosis of breast cancer.

[摘 要] 目的：探讨miR-1207-5p对乳腺癌T47D干细胞增殖、迁移和侵袭的影响及其可能的机制。方法: 以IGF-1、EGF、bFGF诱导、富集乳腺癌T47D干细胞并进行成球培养，流式细胞术分离干细胞，采用WB法检测干细胞分子标志物。采用qPCR检测干细胞中miR-1207-5p的表达水平，双荧光素酶报告基因实验分析miR-1207-5p和LIMD1的靶向关系。CCK-8、Transwell和划痕实验检测T47D干细胞的增殖、迁移和侵袭能力。WB法检测干细胞中LIMD1蛋白的表达水平。结果: 分离的T47D干细胞能够形成细胞球，细胞球体积随培养天数的增加而增加；干细胞分子标志物ALDH1、ESA和OCT4的表达水平较亲本T47D细胞显著升高（P<0.05或P<0.01），miR-1207-5p在干细胞中高表达（P<0.01）。过表达miR-1207-5p显著促进T47D干细胞的增殖、迁移和侵袭（均P<0.01），敲降miR-1207-5p显著抑制T47D干细胞的增殖、迁移和侵袭（均P<0.01）。miR-1207-5p靶向下调LIMD1的表达（P<0.01），miR-1207-5p通过靶向下调LIMD1促进乳腺癌T47D干细胞的增殖、迁移和侵袭能力（P<0.05或P<0.01）。结论： miR-1207-5p通过靶向下调LIMD1的表达来促进乳腺癌T47D干细胞的增殖、迁移和侵袭能力。

Objective:To explore the effect of hyperbaric oxygen (HBO) therapy on the healing of the skin flap, the vascular endothelial growth factor (VEGF) and hypoxia inducing factor-1α (HIF-1α) after modified radical mastectomy.Methods:A total of 132 patients with breast cancer admitted in the Department of Breast Surgery of Heping Hospital Affiliated to Changzhi Medical College from January 2017 to June 2019 were selected as the research subjects and randomly divided into control group ( n=66) and observation group ( n=66). The control group was given the modified radical mastectomy, while the observation group was additionally given hyperbaric oxygen therapy. The postoperative healing condition of incision flap, including healing time, drainage volume, and pain score, was compared between two groups. And the serum VEGF and HIF-1α levels of patients in the two groups were compared before and after the treatment. Besides, postoperative complications were also observed. Results:The healing time of the skin flap in the observation group with HBO [(10.43±0.96) d] was significantly shorter than that in the control group [(13.81±1.15) d]. The drainage volume of the observation group was (274.01±13.10) ml, and the visual analogue scale (VAS) were (4.02±0.34) and (2.84±0.30) on the first and the third day after the operation respectively. The healing condition and VAS scores of the observation group were both better than those in the control group, and all the differences were statistically significant ( P<0.05). Serum VEGF and HIF-1α levels in the observation group were (809.67±40.22) pg/ml and (243.71±22.84) pg/ml respectively, which were significantly improved compared with those before the treatment and those of the control group, and all the differences were statistically significant ( P<0.05). The incidence of postoperative complications in the observation group (3.03%) was lower than that of the control group (10.61%). Conclusion:The hyperbaric oxygen therapy has a significant clinical effect on the patient after the modified radical mastectomy. It can accelerate skin flap healing, relieve patients’ pain, and promote prognosis by reducing HIF-1α level and increasing VEGF content.

Objective:To explore the effect of hyperbaric oxygen (HBO) therapy on the healing of the skin flap, the vascular endothelial growth factor (VEGF) and hypoxia inducing factor-1α (HIF-1α) after modified radical mastectomy.Methods:A total of 132 patients with breast cancer admitted in the Department of Breast Surgery of Heping Hospital Affiliated to Changzhi Medical College from January 2017 to June 2019 were selected as the research subjects and randomly divided into control group ( n=66) and observation group ( n=66). The control group was given the modified radical mastectomy, while the observation group was additionally given hyperbaric oxygen therapy. The postoperative healing condition of incision flap, including healing time, drainage volume, and pain score, was compared between two groups. And the serum VEGF and HIF-1α levels of patients in the two groups were compared before and after the treatment. Besides, postoperative complications were also observed. Results:The healing time of the skin flap in the observation group with HBO [(10.43±0.96) d] was significantly shorter than that in the control group [(13.81±1.15) d]. The drainage volume of the observation group was (274.01±13.10) ml, and the visual analogue scale (VAS) were (4.02±0.34) and (2.84±0.30) on the first and the third day after the operation respectively. The healing condition and VAS scores of the observation group were both better than those in the control group, and all the differences were statistically significant ( P<0.05). Serum VEGF and HIF-1α levels in the observation group were (809.67±40.22) pg/ml and (243.71±22.84) pg/ml respectively, which were significantly improved compared with those before the treatment and those of the control group, and all the differences were statistically significant ( P<0.05). The incidence of postoperative complications in the observation group (3.03%) was lower than that of the control group (10.61%). Conclusion:The hyperbaric oxygen therapy has a significant clinical effect on the patient after the modified radical mastectomy. It can accelerate skin flap healing, relieve patients’ pain, and promote prognosis by reducing HIF-1α level and increasing VEGF content.

Objective:To compare the clinical effects of the two methods in surgical treatment of gynecomastia.Methods:The clinical data of 46 patients with gynecomastia were retrospectively analyzed, who received total removal of the glands through mastoscopic assistance (mastoscopic group) or traditional areola incision (traditional group) from Mar. 2017 to Mar. 2018. The two groups were compared in terms of blood loss, the mean operation duration, extubation time, the average hospitalization time, postoperative complications, the total cost and patients’ satisfaction at 6 month after operation. Chi-square test was used to compare the count data between groups, paired t test was used to compare the measurement data between groups, and SPSS18.0 statistical software was used for statistical analysis.Results:The operation was completed in both groups. There were no differences between the two group in age (0.473) , BMI (0.353) , lesion location (0.198) , Simon classification (0.683) , the mean blood loss ( P=0.999) , mean operation duration ( P=0.596) , extubation time ( P=0.755) , the average hospitalization time ( P=0.676) , postoperative complications and ( P=0.370) or the total cost ( P=0.486) . The difference of patients’ satisfaction at 6 month after operation had statistical significance ( P=0.012) . conclusion:Compared with traditional open surgery, mastoscopic surgery for gynecomastia is minimally invasive, beautiful and safe, which can be widely used in clinical practice.

Objective To analyze the diagnostic value of serum procalcitonin (PCT), C-reactive protein (CRP) and interleukin-6 (IL-6) in the detection of incision infection after breast cancer surgery. Methods A total of 152 breast cancer patients admitted to our hospital from June 2016 to April 2018 were enrolled. All patients were given surgery.According to whether the wound infection occurred after operation, the patients were divided into control group (not infected, n=114) and observation group (infected, n=38). The serum levels of PCT, CRP and IL-6 were measured in the two groups on the 2 nd postoperative day. Results The average operation time and hospital stay in the observation group were longer than those in the control group (P<0.05). The serum levels of PCT, CRP and IL-6 in the observation group were higher than those in the control group (P<0.05). The positive rate of the observation group was higher than that of the control group (P<0.05). Conclusion In patients with breast cancer surgery, serum PCT, CRP and IL-6 detection can provide a good reference for the prediction of postoperative incision infection.